SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, and the University of Texas Medical Branch at Galveston (UTMB), an academic health institution of The University of Texas System, have announced a collaboration to incorporate Viz Subdural software into the Chronic Subdural Hematoma Treatment with Embolization Versus Surgery Study (CHESS).1.

旧金山--（商业新闻短讯）--Viz.ai是人工智能驱动的疾病检测和智能护理协调的领导者，德克萨斯大学加尔维斯顿分校（UTMB）是德克萨斯大学系统的学术健康机构，他们宣布合作将Viz硬膜下软件纳入栓塞与手术研究（CHESS）的慢性硬膜下血肿治疗中。

A chronic subdural hematoma (cSDH) is an old clot of blood on the surface of the brain beneath its outer covering. These liquefied clots most often occur in patients aged 60 and older who have brain atrophy, a shrinking or wasting away of brain tissue due to age or disease.2 As the population ages, cSDH is predicted to be the most common cranial neurosurgical condition by 2030.3 CHESS will collect safety and efficacy data in patients with a moderately symptomatic convexity cSDH..

慢性硬膜下血肿（cSDH）是大脑外层下表面的一块旧血块。这些液化血块最常发生在60岁及以上的患者身上，这些患者因年龄或疾病而出现脑萎缩，脑组织萎缩或消瘦。2随着人口老龄化，预计到2030年cSDH将成为最常见的颅神经外科疾病。3国际象棋将收集中度症状性cSDH患者的安全性和有效性数据。。

“CHESS is designed to be the first US randomized controlled trial to provide evidence on the safety and efficacy of standalone middle meningeal artery embolization (MMAE) vs surgical drainage using particle embolization,” said Peter Kan, MD, MPH, FRCSC, FAANS, Professor and Chair, Department of Neurosurgery, University of Texas Medical Branch.

德克萨斯大学医学院神经外科教授兼主席PeterKan博士说：“CHESS旨在成为美国第一个随机对照试验，为独立脑膜中动脉栓塞（MMAE）与使用颗粒栓塞的手术引流的安全性和有效性提供证据。”。

“Viz.ai’s Subdural tool holds the promise of efficiently identifying prospective participants, thereby aiding in the timely completion of this important trial.”.

“即ai的硬膜下工具有望有效识别潜在参与者，从而有助于及时完成这项重要试验。”。

The Viz Subdural algorithm was approved in 2022 as the first SDH-specific AI-powered detection and care coordination platform with the ability to identify suspected cases of acute and chronic subdural bleeds, and then quickly notify the care team to review the patient case and make a treatment decision if necessary.

Viz硬膜下算法于2022年获得批准，成为第一个SDH特定AI供电的检测和护理协调平台，能够识别疑似急性和慢性硬膜下出血病例，然后迅速通知护理团队审查患者病例，并在必要时做出治疗决定。

In the CHESS trial, Viz.ai will notify investigators immediately when it detects a patient who has suspected SDH and meets the eligibility criteria for enrollment. Study investigators can measure chronic bleeds4 and coordinate subject enrollment easily and securely through Viz.ai’s dynamic, mobile, HIPAA-compliant platform..

在CHESS试验中，当检测到疑似SDH且符合入选资格标准的患者时，Viz.ai将立即通知调查人员。研究人员可以通过ai的动态、移动、符合HIPAA的平台，轻松、安全地测量慢性出血4并协调受试者登记。。

“Patient enrollment is the most time-consuming and costly aspect of the clinical trial process,” said Prem Batchu-Green, Vice President of Clinical at Viz.ai. “By deploying Viz.ai for the CHESS study, we are not only reducing the manual burden of patient identification on research staff but also improving SDH detection and workflow as well as increasing SDH awareness, physician engagement, clinical specialist attendance, and case collaboration.”.

Viz.ai临床副总裁Prem Batchu Green说：“患者登记是临床试验过程中最耗时和最昂贵的方面。通过部署Viz.ai进行CHESS研究，我们不仅减轻了研究人员识别患者的手动负担，而且改进了SDH检测和工作流程，提高了SDH意识，医生参与度，临床专家出勤率和病例协作。”。

1 The study was funded by the National Institute of Neurological Disorders and Stroke, of the National Institutes of Health, under grant award number 1UG3NS128397-01A1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health..

1该研究由美国国立卫生研究院国家神经疾病和中风研究所资助，资助号为1UG3NS128397-01A1。内容完全由作者负责，不一定代表美国国立卫生研究院的官方观点。。

2 Chronic subdural hematomas. UCLA Health. (n.d.). https://www.uclahealth.org/medical-services/neurosurgery/conditions-treated/chronic-subdural-hematomas

2例慢性硬膜下血肿。加州大学洛杉矶分校健康。（不另作说明）。https://www.uclahealth.org/medical-services/neurosurgery/conditions-treated/chronic-subdural-hematomas

3 Hoffman et al. (n.d.). Management of chronic subdural hematoma with the subdural evacuating port system: Systematic review and meta-analysis. https://pubmed.ncbi.nlm.nih.gov/33775320/

3霍夫曼等人（n.d.）。硬膜下撤离口系统治疗慢性硬膜下血肿：系统评价和荟萃分析。https://pubmed.ncbi.nlm.nih.gov/33775320/

4 Viz Subdural is currently available commercially for triage and notification. Measuring SDH is not available for commercial use.

4 Viz硬膜下目前可用于分类和通知。SDH测量不可用于商业用途。

About Viz.ai

关于Viz.ai

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,600+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One™ is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes.

Viz.ai是使用ai算法和机器学习提高美国和欧洲1600多家医院和卫生系统诊断和护理速度的先驱。AI-powered Viz.AI One™是一种智能护理协调解决方案，可识别更多疑似疾病患者，在护理点告知关键决策，优化护理途径并帮助改善结果。

Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai..

在现实世界的临床证据的支持下，Viz.ai One为患者，提供者以及制药和医疗器械公司提供了巨大的价值。有关更多信息，请访问viz。ai。。